In recent years, the benefits of involving PRPs has increasing been recognized. The role is an important one, which goes well beyond the inclusion of patients as study participants.
Pulled Myeloma Drug May Have a Role in Treating the Disease After All
A little more than a year after belantamab mafodotin (Blenrep), an anti-B-cell maturation antigen (BCMA) monoclonal antibody, was withdrawn from the market for patients with
February 8, 2024